# A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

> **NCT02497287** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 802 (actual)

## Conditions studied

- Treatment-resistant Depression

## Interventions

- **DRUG:** Esketamine (Intranasal Spray)
- **DRUG:** Duloxetine (Oral Antidepressant)
- **DRUG:** Escitalopram (Oral Antidepressant)
- **DRUG:** Sertraline (Oral Antidepressant)
- **DRUG:** Venlafaxine Extended Release (XR) (Oral Antidepressant)

## Key facts

- **NCT ID:** NCT02497287
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-30
- **Primary completion:** 2017-10-28
- **Final completion:** 2017-10-28
- **Target enrollment:** 802 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02497287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02497287, "A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02497287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*